Combined treatment with GnRH antagonist and GnRH to control gonadotropin levels in mammals
US5180711A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jun 14, 1990 |
| Grant date | Jan 19, 1993 |
| Priority date | — |
| Expiry date | Jun 14, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/09
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method of controlling gonadotropin levels in mammals which comprises administering a gonadotropin releasing hormone (GnRH) antagonist in an amount and frequency effective to substantially suppress endogenous gonadotropin levels in said mammal and administering gonadotropin releasing hormone (GnRH) in an amount and frequency effective to induce secretion of gonadotropins to maintain a desired level in said mammal. This method is especially useful for treating mammals, particularly women, who suffer from polycystic ovarian disease or hyperandrogenism, or who otherwise have abnormally high levels of luteinizing hormone which it is desired to reduce to approximately normal levels. The method of this invention is particularly advantageous for inducing ovulation in mammals, particularly women, that have the above-mentioned problems. The preferred GnRH antagonists for use in the present invention include Antide and its analogs, which exhibit long term gonadotropin suppression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.